How do you approach choice of second-line therapy in metastatic TNBC after progression on 1L TROP2 ADC?

Unfortunately, we lack prospective randomized data to guide sequencing decisions. Many retrospective series have suggested ADC2 does not perform as well as ADC1. We have also seen high attrition rates line after first line of therapy, arguing to use our most active agents earlier. We do not yet have...

The movement of TROP2 ADCs into the first-line setting, supported by ASCENT-03 and TROPION-Breast02, has created an important unmet need in the post-TROP2 ADC setting. These data are likely to reshape first-line treatment for patients with locally advanced unresectable or metastatic TNBC who are not...